International Journal of Molecular Sciences · 3 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It also outlines potential therapeutic applications, including ex vivo cancer immunotherapy and hereditary disease treatment, and in vivo applications such as treating Leber’s congenital amaurosis, but these are discussed as developments or early-stage trials, not as completed clinical outcomes from this study.
It also outlines potential therapeutic applications, including ex vivo cancer immunotherapy and hereditary disease treatment, and in vivo applications such as treating Leber’s congenital amaurosis, but these are discussed as developments or early-stage trials, not as completed clinical outcomes from this study. The review highlights that CRISPR/Cas technology's simplicity, accuracy, and efficiency make it a widely used tool for genetic engineering.
